<DOC>
	<DOCNO>NCT01682083</DOCNO>
	<brief_summary>This two-arm , randomize , double-blind Phase III study dabrafenib combination trametinib versus two placebo adjuvant treatment melanoma surgical resection . Patients completely resect , histologically confirm , BRAF V600E/K mutation-positive , high-risk [ Stage IIIa ( lymph node metastasis &gt; 1 mm ) , IIIb IIIc ] cutaneous melanoma screen eligibility . Subjects randomize receive either dabrafenib ( 150 milligram ( mg ) twice daily [ BID ] ) trametinib ( 2 mg daily [ QD ] ) combination therapy two placebo 12 month .</brief_summary>
	<brief_title>A Study BRAF Inhibitor Dabrafenib Combination With MEK Inhibitor Trametinib Adjuvant Treatment High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Completely resect histologically confirm highrisk [ Stage IIIa ( LN metastasis 1 mm ) , IIIb IIIc cutaneous melanoma determine V600E/K mutation positive central laboratory . Patients present initial resectable lymph node recurrence diagnosis Stage I II melanoma eligible . Surgically render free disease 12 week randomization . Recovered definitive surgery ( e.g . uncontrolled wound infection indwell drain ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . Adequate hematologic , hepatic , renal cardiac function . Known mucosal ocular melanoma presence unresectable intransit metastasis . Evidence distant metastatic disease . Prior systemic anticancer treatment radiotherapy melanoma ; prior surgery melanoma allow . History another malignancy concurrent malignancy include prior malignant melanoma . Exceptions include : Patients diseasefree 5 year patient history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible , example cervical cancer situ , atypical melanocytic hyperplasia melanoma situ , multiple primary melanoma , malignancy patient disease free &gt; 5 year . History current evidence cardiovascular risk . History current evidence retinal vein occlusion ( RVO ) central serous retinopathy ( CSR )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>trametinib</keyword>
	<keyword>Oncology</keyword>
	<keyword>adjuvant melanoma</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>dabrafenib trametinib combination therapy</keyword>
	<keyword>BRAF mutation-positive melanoma</keyword>
	<keyword>BRAF inhibitor</keyword>
</DOC>